Coronavirus, COVID-19, Pneumonia, Pneumocystis
Conditions
Keywords
Pneumonia, COVID-19, hydroxychloroquine
Brief summary
The study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of COVID-19 pneumonia.
Detailed description
There is no vaccine or antiviral treatment for human coronavirus, so this study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of COVID-19 pneumonia.
Interventions
DRUGHydroxychloroquine
Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments
Sponsors
Shanghai Public Health Clinical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The participants were diagnosed as COVID-19 pneumonia, according to the notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 4 or update version) made by National Health Commission of the People's Republic of China; * Participants aged over 18; * Written the informed consent.
Exclusion criteria
* Hypersensitivity to chloroquine or hydroxychloroquine; * Women during pregnancy; * Severe heart, lung, kidney, brain, blood diseases or other important systemic diseases; * Participants with retinal disease, hearing loss; * Participants with severe neurological and mental illness; * Subjects were considered to be unable to complete the study, or not suitable for the study by researchers. Exit criteria: * Subjects asked to withdraw the study * Subject will benefit if withdraw according to researchers' suggestions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3 | 3 days after randomization |
| The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5 | 5 days after randomization |
| The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7 | 7 days after randomization |
| The mortality rate of subjects at weeks 2 | 14 days after randomization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | 14 days after randomization | — |
| The critical illness rate of subjects at weeks 2 | 14 days after randomization | The diagnosis of critical illness case was based on the notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 4) made by National Health Commission of the People's Republic of China. |
Countries
China
Outcome results
None listed